Dyadic International (DYAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 May, 2026Executive summary
The annual meeting will be held virtually on June 18, 2026, with shareholders voting on key proposals including director election, a reverse stock split, auditor ratification, and executive compensation approval.
Shareholders of record as of April 24, 2026, are entitled to vote, with 36,438,703 shares outstanding.
Voting can be conducted online, by phone, mail, or during the virtual meeting, with detailed instructions provided.
The board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1: Election of one Class I director (Seth J. Herbst, M.D.) for a term expiring in 2029.
Proposal 2: Authorization for a reverse stock split at a ratio between 2:1 and 10:1, at the board's discretion, to address Nasdaq listing compliance.
Proposal 3: Ratification of Crowe LLP as independent auditor for 2026.
Proposal 4: Advisory vote on 2025 executive compensation.
Shareholder proposals for the 2027 meeting must be submitted by January 11, 2027.
Board of directors and corporate governance
The board consists of four members, with a classified structure and separation of CEO and Chairman roles.
All directors attended 2025 board and committee meetings; independence is determined per Nasdaq standards.
Committees include Audit, Compensation, and Nominating, each with defined charters and independent members.
The board actively oversees risk, including financial, compliance, and IT risks.
Shareholder communications are facilitated through direct correspondence with the board.
Latest events from Dyadic International
- C1 platform delivers rapid, high-yield, animal-free biologics with proven safety and global validation.DYAI
Investor presentation1 May 2026 - Net loss widened to $7.36M on lower revenue, with expanded commercialization and partnerships.DYAI
Q4 202525 Mar 2026 - Commercial product launches and partnerships are driving revenue growth, with more expected by 2027.DYAI
Life Sciences Virtual Investor Forum12 Mar 2026 - Rapid commercialization in non-therapeutic markets targets profitability by 2026.DYAI
Small-Cap Virtual Conference3 Feb 2026 - New partnerships and strong cash position support growth despite lower Q2 revenue.DYAI
Q2 20241 Feb 2026 - Q3 2024 revenue up 5x, net loss narrowed, and cash reserves reached $10M.DYAI
Q3 202414 Jan 2026 - Revenue growth, narrowed losses, and major grants set up multiple product launches in 2025.DYAI
Q4 202419 Dec 2025 - Registering 840,384 shares for resale from convertible notes; no proceeds to the company.DYAI
Registration Filing16 Dec 2025 - Shifted to commercial focus with first bulk sales, global expansion, and strong liquidity.DYAI
Q3 202515 Dec 2025